"Authentic Big Law" – Can we practice law at the very highest levels, while also in a personal, caring and team-focused way that rejects discrimination and self-promotion at the cost of others, and truly reflects the ideals we hold onto so dearly outside of work? We here at Team Cooley answer that question with a resounding "yes!"
Charlie Kim skillfully navigating your capital markets transactions - priceless. Charlie's depth and breadth of knowledge/experience was crucial in the successful execution of our IPO and multiple follow-on offerings which tallied to over $1.2 billion. Internally, we nicknamed Charlie the 'Ironman of Capital Markets'. He and his team were a pleasure to partner with from the pre-planning phase all the way through the end of the process.
Admissions and credentials
California
New York
Rankings and accolades
Chambers USA: Band 1: Capital Markets: Debt & Equity – California (2017 – 2025)
Chambers USA: Band 1: Capital Markets: Debt & Equity: Western United States – Nationwide (2019 – 2025)
The Legal 500 US: Leading Lawyer in Capital Markets: Equity Offerings (2024 – 2025)
Daily Journal: Top 100 Lawyer across all specialties in California and recipient of the California Lawyer Attorneys of the Year Award
The Daily Transcript: San Diego Top Attorney
Law360: MVP of the Year – Capital Markets
Thomson Reuters: Super Lawyer – Southern California and San Diego
Memberships and affiliations
American Bar Association (ABA)
Council of Korean Americans
New York State Bar Association
San Diego County Bar Association
Representative Issuers
Charlie has represented companies/investment banks on capital markets transactions involving issuers across industries, such as: AbCellera, Accelerate, ACELYRIN, Acutus, Advaxis, Aerohive, Agenus, Akari, Akcea, Akero, Allogene, Alteryx, Ambrx, Amylin, Anadys, AnaptysBio, Angion, Annexon, Anthera, Apogee, Applied Molecular Transport, Arcadia, Arcus, Arcutis, Ardea, Arena, Aridis, Ascendis, ASLAN, Athira, Audentes, Avidity, Ballast Point Brewing & Spirits, Beta Bionics, Biomea, Boundless Bio, Cadence, CARGO, Castlight, Cerus, CG Oncology, Cidara, Clorox, Corcept, Crinetics, Cue Health, Cyan, Cytori, Day One, Dermira, Design, DICE, Doximity, Dynavax, eBay, EHang, Eidos, Elevation Oncology, Entropic, Erasca, Exagen, Evofem, Fangdd, FIGS, FireEye, Five Prime, Gemphire, Genomatica, Global Blood, Gossamer, Gracell, Graphite Bio, Gritstone, Guardant Health, Halozyme, Health Catalyst, Healthcare Royalty, HealthEquity, Horizon, IGM, Ignyta, Immune Design, IMV, Inhibrx, Inovio, Invitae, Ionis, Janux, Jazz Pharmaceuticals, Kamada, Kinnate, Kite Pharma, Kronos, Landry’s, LifeLock, Limelight, Livongo, Longboard, Lyell, MannKind, Medallia, MethylGene, Metropark, MindBody, Minerva, Mirati, NantHealth, NantKwest, Nektar, Neon, Neumora, Neurocrine, ObsEva, Olink, Ooma, Optimer, ORIC, Otonomy, Pernix, Phathom, Poseida, PRA Holdings, PROCEPT, Progressive Gaming, ProNAi, ProQR, Proto Labs, Qualtrics, Quidel, Radiant Systems, Rani, Raptor, RayzeBio, Reata, Receptos, Regulus, ReSearch Pharmaceutical Services, Sana, Sangamo, Santarus, Savara, Seattle Genetics, Septerna, Senomyx, Sequenom, ShockWave, Sierra, Silverback, Singular Genomics, Somaxon, Strongbridge, Structure, Surface Oncology, Sutro, Syndax, Tableau Software, Tabula Rasa, Taiwan Liposome Company, Tangoe, Tarsus, Third Harmonic, TRACON, Treace, Tricida, Trius, TriVascular, Uber Technologies, Upstream, Vaxcyte, Ventyx Biosciences, Verenium, Verona, Vical, ViewRay, Viking, Vir, Vital Therapies, Vor, Xencor, Xenon, XenoPort, Zealand Pharma, Zentalis, Zogenix, Zscaler, Zymeworks, 4D Molecular Therapeutics,10x Genomics and 89bio.